TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10642460

Group type: EXPERIMENTAL
Intervention: Workplace-based lifestyle intervention (Workscreen)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1206
Study: 8925642

Group type: EXPERIMENTAL
Intervention: Sulfate-bicarbonate mineral water
Number of subjects: 9

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 9
Study: 1377741

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Open treatment phase
Number of subjects: 866
Study: 6365417

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 19
Study: 31466305

Group type: EXPERIMENTAL
Intervention: Maple products (6% CHO solution)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Commercial sports drink (6% CHO solution)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Glucose (control CHO solution)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Water (control solution)
Number of subjects: 85
Study: 29947247

Group type: EXPERIMENTAL
Intervention: Liraglutide (n=63)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (n=85)
Number of subjects: 148
Study: 25619125

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) with lowest PAO quartiles
Number of subjects: 274
Study: 24576509

Group type: EXPERIMENTAL
Intervention: LapSim
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21887548

Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Inside-out transobturator (TVT-O)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All groups (TVT, TOT, TVT-O)
Number of subjects: 160
Study: 20626355

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 4 mg at the end of surgery and 12 mg added to PCA (group O)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intravenous ramosetron 0.3 mg at the end of surgery and no antiemetics added to PCA (group R1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intravenous ramosetron 0.3 mg at the end of surgery and 0.6 mg added to PCA (group R2)
Number of subjects: 320

Group type: COMPARATOR
Intervention: No prophylactic antiemetics (group P)
Number of subjects: 320
Study: 17717627

Group type: EXPERIMENTAL
Intervention: 80 g of mixed cruciferous vegetables
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 350 g of mixed cruciferous vegetables
Number of subjects: 6
Study: 16310607

Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin for routine thromboprophylaxis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin for specific high-risk patients
Number of subjects: 22
Study: 12037271

Group type: EXPERIMENTAL
Intervention: Act‐Hib in combination with BE DTwP (Group A, n = 160)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: TetrAct‐Hib (Group B, n = 160)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: BE DTwP and Act‐Hib as separate injections (Group C, n = 58)
Number of subjects: 378
Study: 9873862

Group type: EXPERIMENTAL
Intervention: 3 MU of alpha interferon thrice weekly (TIW) for 3 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Individualized dose regimen tapering interferon dose from 3 or 6 MU by one-third every 2 months if transaminases were persistently normal
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Fixed dose regimen (3 or 6 MU thrice weekly)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (biochemical nonresponders followed for an additional 6 months)
Number of subjects: 49
Study: 7884542

Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 18O-cholesterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 13C5-cholesterol
Number of subjects: 12
Study: 31789476

Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 69

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: nal-IRI monotherapy
Number of subjects: 69
Study: 31578954

Group type: EXPERIMENTAL
Intervention: elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily
Number of subjects: 167

Group type: COMPARATOR
Intervention: tenofovir disoproxil fumarate (300 mg)
Number of subjects: 167
Study: 28960482

Group type: EXPERIMENTAL
Intervention: Combined group (iron chelator plus amlodipine)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (iron chelator)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 25362980

Group type: EXPERIMENTAL
Intervention: Tightened tourniquet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Loosen tourniquet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 23698590

Group type: EXPERIMENTAL
Intervention: +276T-allele carriers
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: +45T>G SNP, GG subjects
Number of subjects: 168
Study: 21828392

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (Group A) - early coronary angiography within 48 hours with intended revascularization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ischemia-guided strategy (Group B) - catheterization based on myocardial ischemia and viability
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ischemia-guided strategy (Group B)
Number of subjects: 60
Study: 19634823

Group type: EXPERIMENTAL
Intervention: Augmentation plate fixation with or without autogenous cancellous bone graft
Number of subjects: 38
Study: 16702888

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d or more (n = 120)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Risperidone 3 mg/d or more (n = 115)
Number of subjects: 235
Study: 15380399

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine plus sustained clonazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine plus brief clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11761130

Group type: EXPERIMENTAL
Intervention: Interactive Metronome training (15 hours)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Computer video games training (Control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interactive Metronome training
Number of subjects: 56
Study: 8985298

Group type: EXPERIMENTAL
Intervention: Lamivudine 25 mg daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8107547

Group type: EXPERIMENTAL
Intervention: Iron supplementation (100 mg.d-1)
Number of subjects: 20
Study: 2959883

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Salbutamol + Ipratropium Bromide
Number of subjects: 9
Study: 29582150

Group type: EXPERIMENTAL
Intervention: Artifact-corrected neurofeedback (AC NF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-artifact-corrected neurofeedback (NAC NF)
Number of subjects: 14
Study: 27526120

Group type: EXPERIMENTAL
Intervention: MP4CO (15 mg/kg/dose to 172 mg/kg/dose, single IV doses; two cohorts received fractionated doses of 172 or 344 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MP4CO
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MP4CO and NS
Number of subjects: 24
Study: 23974954

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Infliximab plus Azathioprine
Number of subjects: 508

Group type: COMPARATOR
Intervention: CDAI (cut-off 150)
Number of subjects: 508
Study: 22819313

Group type: EXPERIMENTAL
Intervention: Extended PLND
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard PLND
Number of subjects: 360
Study: 20537746

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg twice-daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 18714075

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PDA) regarding the use of natural health products (NHPs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General information brochure about menopause
Number of subjects: 90
Study: 16149743

Group type: EXPERIMENTAL
Intervention: Formula fortified with NT at 34 mg/L
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control formula with an innate level of NT at 10 mg/L
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Breastfed infants (reference group)
Number of subjects: 200
Study: 14648962

Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF) applied to wound edges
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control (water) applied to wound edges
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF)
Number of subjects: 227
Study: 10565626

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy volunteers (8 subjects)
Number of subjects: 38
Study: 8706481

Group type: EXPERIMENTAL
Intervention: Patients with ARDS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control patients without lung injury
Number of subjects: 12
Study: 1651857

Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clinical criteria (CC) and manual evaluation of TOF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clinical criteria (CC) only
Number of subjects: 90
Study: 7034669

Group type: EXPERIMENTAL
Intervention: Physical therapy and occupational therapy in the stroke unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy and occupational therapy in medical units
Number of subjects: 0
Study: 31256761

Group type: EXPERIMENTAL
Intervention: Plan C (standard rapid rehydration using Ringer's lactate 100 ml/kg over 3 hours, incorporating 0.9% saline boluses for children with shock)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Slow rehydration (100 ml/kg Ringer's lactate over 8 hours without boluses)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Plan C
Number of subjects: 122

Group type: COMPARATOR
Intervention: Slow rehydration
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 122
Study: 30095637

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide/salbutamol sulfate (COM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate (VEN)
Number of subjects: 0
Study: 27255588

Group type: EXPERIMENTAL
Intervention: smalltalk group‐only program
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: smalltalk plus (group program plus home coaching)
Number of subjects: 2186

Group type: COMPARATOR
Intervention: standard care (control)
Number of subjects: 2186
Study: 24821196

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine hydrochloride (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 20
Study: 22759785

Group type: EXPERIMENTAL
Intervention: Dietary advice (intervention group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 138
Study: 19740900

Group type: EXPERIMENTAL
Intervention: Infliximab every 6 weeks (Q6)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Infliximab on demand (DEM)
Number of subjects: 230
Study: 17667569

Group type: EXPERIMENTAL
Intervention: IgE for rocuronium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgE for suxamethonium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgE for morphine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgE for pholcodine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ROC analysis for rocuronium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ROC analysis for suxamethonium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ROC analysis for morphine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ROC analysis for pholcodine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgE inhibition tests
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Total IgE analysis
Number of subjects: 55
Study: 16401960

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (13 fractions, 3.0 Gy per fraction, and 4 fractions at 4.5 Gy per fraction, total dose of 57 Gy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (37 fractions, 2.0 Gy per fraction, total dose of 74 Gy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified treatment, but included in the study)
Number of subjects: 22
Study: 12417069

Group type: EXPERIMENTAL
Intervention: Hemocoagulase
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lizhixue
Number of subjects: 180

Group type: COMPARATOR
Intervention: Manitol hexanitrate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hemocoagulase and Lizhixue
Number of subjects: 180
Study: 10613619

Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen plus 60 mg codeine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen plus 60 mg codeine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acetaminophen plus codeine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 120
Study: 7864704

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg single dose
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg BID for 7 days
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg BID for 3 days
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg BID for 3 days
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily for 3 days
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily for 5 days
Number of subjects: 970

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg BID for 7 days
Number of subjects: 970
Study: 2022937

Group type: EXPERIMENTAL
Intervention: Office cholesterol testing (study group)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No office cholesterol testing (control group)
Number of subjects: 4
Study: 6804651

Group type: EXPERIMENTAL
Intervention: 10% safflower oil emulsion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 20% safflower oil emulsion
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (10% safflower oil emulsion)
Number of subjects: 5
Study: 29040946

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 108
Study: 27633391

Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Baseline glutamate levels
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Baseline glutamine-to-glutamate ratio
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Changes in metabolites after 1 year
Number of subjects: 980
Study: 26386799

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 952

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 952
Study: 24163292

Group type: EXPERIMENTAL
Intervention: Pesinet programme (telehealth service)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study: 20691824

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17703100

Group type: EXPERIMENTAL
Intervention: *B/*C genotype (high ACP1 activity)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 300
Study: 16794028

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (3 h/day, 5 days/wk at 4,000‐5,500 m)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normoxic (placebo)
Number of subjects: 23
Study: 12880731

Group type: EXPERIMENTAL
Intervention: Banana leaf dressing (BLD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Boiled potato peel bandage (BPPB)
Number of subjects: 30
Study: 11199613

Group type: EXPERIMENTAL
Intervention: Resin-based composite restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 0
Study: 9058224

Group type: EXPERIMENTAL
Intervention: 2 mL of 0.25% bupivacaine
Number of subjects: 135

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 135
Study: 8382840

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-8 at a concentration of 10 nm
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy individuals and MDS patients)
Number of subjects: 8
Study: 3959564

Group type: EXPERIMENTAL
Intervention: Counselor identified as a recovering alcoholic
Number of subjects: 42

Group type: COMPARATOR
Intervention: Counselor not identified as a recovering alcoholic
Number of subjects: 42
Study: 30273892

Group type: EXPERIMENTAL
Intervention: Depressed women with childhood emotional abuse
Number of subjects: 52

Group type: COMPARATOR
Intervention: Depressed women without childhood emotional abuse
Number of subjects: 52

Group type: COMPARATOR
Intervention: Never-depressed women without childhood emotional abuse
Number of subjects: 52
Study: 26714202

Group type: EXPERIMENTAL
Intervention: SSRI treatment (escitalopram or sertraline)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: SNRI treatment (venlafaxine)
Number of subjects: 1008
Study: 25109096

Group type: EXPERIMENTAL
Intervention: Women who experienced IPV
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Women who did not experience IPV
Number of subjects: 2621
Study: 23650968

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 200 μg/100 μl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC) 200 µg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 24
Study: 20603855

Group type: EXPERIMENTAL
Intervention: Biennial FOBT screening
Number of subjects: 105000

Group type: COMPARATOR
Intervention: Control group (unscreened)
Number of subjects: 105000
Study: 18256417

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii for five days in addition to oral rehydration solution (ORS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ORS alone (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 100
Study: 16895629

Group type: EXPERIMENTAL
Intervention: 10,000 IU of HCG (group 1, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: HCG 1500 IU, 12 h after ovulation induction (group 2, n = 17)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HCG 1500 IU 35 h after ovulation induction (group 3, n = 13)
Number of subjects: 45
Study: 14626378

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after local excision (LE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local excision (LE) with margin width > or = 1 cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin-sparing mastectomy (SSM) with autologous myocutaneous flap reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 0
Study: 10776679

Group type: EXPERIMENTAL
Intervention: Before-Discharge Intervention Method (BDIM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no BDIM)
Number of subjects: 0
Study: 8636581

Group type: EXPERIMENTAL
Intervention: Postprandial blood pressure changes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postural blood pressure changes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postprandial hypotension
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both postprandial and orthostatic hypotension
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cardiovascular medications
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intra-class correlation of postprandial systolic BP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intra-class correlation of postural systolic BP
Number of subjects: 22
Study: 1336356

Group type: EXPERIMENTAL
Intervention: Type I, insulin‐dependent diabetic subjects with microalbuminuria
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normoalbuminuric type I, insulin‐dependent diabetic subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 2866786

Group type: EXPERIMENTAL
Intervention: Bucindolol 50, 100 and 200 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oxprenolol 40, 80 and 160 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg
Number of subjects: 7